Aarkstore - Metastatic Renal Cell Carcinoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Aarkstore - Metastatic Renal Cell Carcinoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Description:

The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Metastatic Renal Cell Carcinoma Browse full report @ – PowerPoint PPT presentation

Number of Views:53

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Metastatic Renal Cell Carcinoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015


1
Aarkstore - Metastatic Renal Cell
Carcinoma-Global API Manufacturers, Marketed and
Phase III Drugs Landscape, 2015
Category Pharmaceuticals and Healthcare
2
Metastatic Renal Cell Carcinoma-Global API
Manufacturers, Marketed and Phase III Drugs
Landscape, 2015, Report provides comprehensive
insights about phase III pipeline drugs and
marketed drugs across the Metastatic Renal Cell
Carcinoma. A key objective of DelveInsights
report is to establish the understanding for API
Manufacturers for marketed and Phase III Pipeline
drugs across the different countries and regions
for the drugs falling under Metastatic Renal Cell
Carcinoma. The Report gives insights into patents
providing thepatent protection data and marketing
exclusivity of all the drugs across the
Metastatic Renal Cell Carcinoma. While the
leading brands, companies and chemicals are
considered thoroughly, DelveInsights report also
provides details on the Global API Manufacturers
across the globe covering Drug Master
FilingsofUS, Europe and API Manufacturers in Asia
specifically China and India. The research
analysis also presents the global sales forecasts
data till 2016.
Browse Complete Report http//www.aarkstore.com
/pharmaceuticals-healthcare/98056/metastatic-renal
-cell-carcinoma-global-api-manufacturers-marketed-
and-phase-iii-drugs-landscape-2015
3
Data Sources
  • The report is built using data and information
    sourced from proprietary databases, primary and
    secondary research and in-house analysis by
    DelveInsight team of industry experts.
  • Secondary sources information and data has been
    collected from various printable and
    non-printable sources like search engines, News
    websites, Government Websites, Trade Journals,
    White papers, Magazines, Trade associations,
    Books, Industry Portals, Industry Associations
    and access to available databases.
  • Please note This report requires certain
    updates. We have all the information available
    but require 3 business days to complete the
    process and ensure it is as up-to-date as
    possible. Certain sections in the report may be
    removed or altered based on the availability and
    relevance of data for the indicated disease.
  • .

4
Scope
  • A snapshot of the global Market therapeutics
    scenario for Metastatic Renal Cell Carcinoma.
  • A review of the marketed products under
    prescription for Metastatic Renal Cell Carcinoma,
    regulatory information and marketing status.
  • Coverage of global patent coverage and detailed
    commentaries on the US patent challenges.
  • Graphical representation of investigational
    products for patent expiry and market
    exclusivities across the globe.
  • Product profiles for marketed products for
    Metastatic Renal Cell Carcinoma with complete
    description of mechanism of action, therapeutic
    class, target, route(s) of administration and
    chemical details.
  • Coverage of API Manufacturers for Metastatic
    Renal Cell Carcinoma drugs in the United States,
    Europe and Asian Regions with location details.
  • Coverage of Regulatory filings in theUS, Europe,
    and Asia specifically India and China for
    Metastatic Renal Cell Carcinoma drugs.

5
Reasons to buy
  • Evaluate the marketing status and exclusivity
    details of Metastatic Renal Cell Carcinoma key
    products to exploit opportunities for generic
    drug development opportunities.
  • Identify and understand important and diverse
    types of therapeutics under Phase III development
    for Metastatic Renal Cell Carcinoma.
  • Design effective counter-strategies to gain
    competitive advantage by identifying the key
    patent expiry details and exclusivity with
    respect to Metastatic Renal Cell Carcinoma.
  • API intelligence over marketed drugs for
    Metastatic Renal Cell Carcinoma and gaining
    primary intelligence over active ingredients
    manufacturers across the globe.
  • API intelligence over leading Phase III Pipeline
    drugs.
  • Develop and design strategies by identifying the
    API manufacturers for Phase III Pipeline products
    to enhance and expand business potential and
    scope.

6
Table of Content
  • Indication Overview
  • Marketed Drugs
  • Marketed Details of Drugs by Application Type
  • Marketed Details of Drugs (NDA) by Marketing
    Status
  • Marketed Details of Drugs by Patent Expiration
    Timeline
  • Active Pharmaceutical Ingredient (API)
    Manufacturers Assessment
  • API Manufacturers by United States Drug Master
    File (US DMF) Status
  • API Manufacturers by US DMF Status (Drug
    Specific)
  • API Manufacturers in Europe by Country
  • API Manufacturers in India by State
  • API Manufacturers in China by Province
  • Marketed Details of Approved Drugs by Geography
  • Active Pharmaceutical Ingredient (API)
    Manufacturers Assessment for Phase III Pipeline
    Drugs

7
List of Tables
  • Metastatic Renal Cell Carcinoma Therapeutic
    Market, US, Marketed Drugs by Application Type,
    2015
  • Metastatic Renal Cell Carcinoma Therapeutic
    Market, US, Marketed Drugs by Marketing Status,
    2015
  • Metastatic Renal Cell Carcinoma Therapeutic
    Market, US, (Year), 2015
  • Metastatic Renal Cell Carcinoma Marketed Drugs,
    API Manufacturers by US DMF Status, 2015
  • Metastatic Renal Cell Carcinoma Marketed Drugs,
    US DMF Status Drug Specific (Number), 2015
  • Metastatic Renal Cell Carcinoma Drugs, API
    Manufacturers, Europe by Country, 2015
  • Metastatic Renal Cell Carcinoma Drugs, API
    Manufacturers, India by State, 2015
  • Metastatic Renal Cell Carcinoma Drugs, API
    Manufacturers, China by Province, 2015
  • Metastatic Renal Cell Carcinoma Drugs, API
    Manufacturers by Geography 2015
  •  
  •  

8
List of Figures
  • Metastatic Renal Cell Carcinoma Therapeutic
    Market, US, Marketed Drugs by Application Type
    (), 2015
  • Metastatic Renal Cell Carcinoma Therapeutic
    Market, US, Marketed Drugs by Marketing Status
    (), 2015
  • Metastatic Renal Cell Carcinoma Therapeutic
    Market, US, (Year), 2015
  • Metastatic Renal Cell Carcinoma Marketed Drugs,
    API Manufacturers by US DMF Status (), 2015
  • Metastatic Renal Cell Carcinoma Marketed Drugs,
    US DMF Status Drug Specific (Number), 2015
  • Metastatic Renal Cell Carcinoma Drugs, API
    Manufacturers, Europe by Country, 2015
  • Metastatic Renal Cell Carcinoma Drugs, API
    Manufacturers, India by State, 2015
  • Metastatic Renal Cell Carcinoma Drugs, API
    Manufacturers, China by Province, 2015

9
Related reports
  •  
  • Partnerships, Licensing, Investments and MA
    Deals and Trends for January 2015 in
    Pharmaceuticals
  • EpiCast Report Sepsis - Epidemiology Forecast to
    2023
  • Myasthenia Gravis Global Clinical Trials Review,
    H1, 2015
  • Acute Renal Failure (ARF) (Acute Kidney Injury)
    Global Clinical Trials Review, H1, 2015
  • OpportunityAnalyzer Dengue Vaccines -
    Opportunity Analysis and Forecasts to 2020 -
    Event-Driven Update
  • Global Epinephrine Autoinjector Market 2015-2019
  • Human Growth Hormone Market in the US 2015-2019
  • Global Acute Coronary Syndrome (ACS) Market
    2015-2019
  • Global Automated External Defibrillator Market
    2015-2019
  • Global Gaucher Disease Market 2015-2019

10
  • Metastatic Renal Cell Carcinoma-Global API
    Manufacturers, Marketed and Phase III Drugs
    Landscape, 2015
  • Published Feb 2015 100 Pages
  • Metastatic Renal Cell Carcinoma-Global API
    Manufacturers, Marketed and Phase III Drugs
    Landscape, 2015, Report provides comprehensive
    insights about phase III pipeline drugs and
    marketed drugs across the Metastatic Renal Cell
    Carcinoma.
  • Price

Format Price
PDF 2000
Site License 4000
Enterprise Wide License 6000
11
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com